Berger Montague Sues Beta Bionics Over Stock Fraud Claims

Berger Montague PC, a leading national plaintiffs' law firm, has announced a securities fraud class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), the company's sole commercialized product, the iLet Bionic Pancreas insulin pump. The lawsuit, filed on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025, through February 24, 2026, alleges that the company and certain of its officers misled investors about the safety and efficacy of the iLet device. According to the complaint, after the Company disclosed that it had received a Form 483 notice from the FDA following an inspection of its manufacturing facility, Beta Bionics repeatedly assured investors that the FDA's observations concerned only its handling of customer complaints, as opposed to any underlying safety or efficacy issue with the iLet device. However, the suit alleges that the FDA's findings implicated the Company's quality management system, its investigation and correction of device malfunctions, and its risk analysis for the device itself. Moreover, the complaint states that the Company had failed to report serious injuries. As this information was revealed to investors, the price of Beta Bionics common stock declined, and investors suffered losses.

The deadline to apply for lead plaintiff appointment is November 3, 2026. Investors who purchased or acquired Beta Bionics securities during the Class Period are encouraged to contact Berger Montague for more information. The law firm, Berger Montague PC, is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. The firm is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

The release states these figures. Each one belongs in your article, written exactly as it appears here, in the place it belongs:

- Pennsylvania, (Newsfile Corp. - September 22, 2026) - Berger Montague PC, a leading national plaintiffs' law firm, has announced a securities fraud class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), the company's sole commercialized product, the iLet Bionic Pancreas insulin pump. The lawsuit, filed on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025, through February 24, 2026, alleges that the company and certain of its officers misled investors about the safety and efficacy of the iLet device. According to the complaint, after the Company disclosed that it had received a Form 483 notice from the FDA following an inspection of its manufacturing facility, Beta Bionics repeatedly assured investors that the FDA's observations concerned only its handling of customer complaints, as opposed to any underlying safety or efficacy issue with the iLet device. However, the suit alleges that the FDA's findings implicated the Company's quality management system, its investigation and correction of device malfunctions, and its risk analysis for the device itself. Moreover, the complaint states that the Company had failed to report serious injuries. As this information was revealed to investors, the price of Beta Bionics common stock declined, and investors suffered losses.

- the period from July 30, 2025 through February 24 - had received a Form 483 notice from the FDA - States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. The firm is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.